What is the appropriate management for a 16-year-old male with repaired tetralogy of Fallot, vestibular migraine treated with coenzyme Q10, who vapes marijuana and nicotine and has diffuse stridor‑type lung sounds?

Immediate Cessation of Vaping and Urgent Pulmonary Evaluation

This 16-year-old with repaired TOF must immediately stop all vaping (both marijuana and nicotine) and undergo urgent pulmonary evaluation with chest imaging and pulmonary function testing to assess for vaping-associated lung injury (EVALI) or other pulmonary pathology. The presence of diffuse stridor-type sounds throughout all lung lobes in a patient with repaired TOF who vapes is a serious red flag requiring immediate action.

Critical Priorities

1. Stop All Vaping Immediately

The combination of marijuana and nicotine vaping poses severe respiratory risks:

• Vaping-associated lung injury can cause bilateral ground-glass opacities, respiratory failure, and requires corticosteroid therapy 1
• Cannabis smoking and dual vaping/smoking increase odds of respiratory symptoms by 3-4 fold 2
• Nicotine is an airway irritant that can cause bronchospasm 3
• Young adults using both cannabis vaping and smoking have 4.36 times increased odds of developing functionally important respiratory symptoms 2

Common pitfall: Assuming "stridor-type sounds" are benign or related to TOF alone. In a vaping adolescent, this demands immediate investigation for EVALI, bronchospasm, or structural airway injury.

2. Urgent Pulmonary Workup

Order immediately:

• High-resolution chest CT: Look for ground-glass opacities, subpleural sparing, or other infiltrates characteristic of EVALI 1
• Pulmonary function tests: Assess for restrictive or obstructive patterns
• Inflammatory markers: CBC with differential, CRP, ESR
• Infectious workup: Rule out pneumonia or other infections
• Arterial blood gas or pulse oximetry: Assess oxygenation status

The stridor-type sounds could represent:

• Vaping-induced bronchospasm or inflammation
• EVALI (even with "nicotine-free" products) 1
• Airway irritation from chemical by-products 4
• Underlying pulmonary pathology unmasked by vaping

3. Cardiac Evaluation in Context of TOF

All patients with repaired TOF require at least annual follow-up with an ACHD cardiologist 5. This patient needs:

• Comprehensive echocardiography at an ACHD center to evaluate 5:

  • Residual pulmonary regurgitation (most common post-repair problem)
  • RV dilation and dysfunction
  • Residual RVOT obstruction
  • Tricuspid regurgitation
  • Progressive aortic regurgitation

• Consider cardiac MRI for precise RV volume and function assessment 5

• ECG and consider Holter monitoring: Screen for arrhythmias, which can cause sudden death in repaired TOF 6

Critical consideration: Nicotine causes catecholamine release and tachycardia 3, which could unmask or worsen arrhythmias in this high-risk TOF population where sudden death occurs at ~2 deaths per 1000 patient-years 6.

4. Genetic Screening

Screen for 22q11 deletion syndrome (Class I recommendation) 5:

• Present in significant proportion of TOF patients
• Associated with immune deficits, endocrine disorders, psychiatric conditions 7
• May influence management of vestibular migraines and other comorbidities

5. Address Vestibular Migraine Management

While CoQ10 has some evidence for migraine prevention:

• CoQ10 reduces migraine attack frequency by approximately 1.87 attacks/month 8
• Does not significantly affect severity or duration 8
• Generally well-tolerated 9

However, in this clinical context:

• Ensure the patient is actually taking CoQ10 as prescribed
• Consider adding prophylactic medications with stronger evidence: propranolol, topiramate, or amitriptyline 10
• Avoid propranolol if bronchospasm is confirmed (contraindicated in asthma) 10
• Lamotrigine is preferred if vertigo is more frequent than headaches 10

6. Nicotine Cessation Strategy

For this 16-year-old:

• Behavioral interventions are first-line 11
• Consider varenicline or bupropion (conditional recommendations for adolescents 10-18 years) 11
• Avoid nicotine replacement therapy in this patient: Given his cardiac history and current respiratory symptoms, nicotine replacement products could worsen bronchospasm 3 and are contraindicated in severe bronchospastic disease 3

Critical warning: Nicotine replacement should not be used in patients with severe bronchospastic airway disease, and other forms may be preferable 3.

Algorithmic Approach

Step 1: Immediate cessation of all vaping products
Step 2: Urgent chest CT and PFTs within 24-48 hours
Step 3: If ground-glass opacities present → Treat as EVALI with corticosteroids and supportive care 1
Step 4: Comprehensive ACHD cardiology evaluation with echo/MRI
Step 5: Genetic testing for 22q11 deletion
Step 6: Optimize migraine prophylaxis with evidence-based medications
Step 7: Structured nicotine cessation program with behavioral therapy ± pharmacotherapy

Key Pitfalls to Avoid

1. Dismissing respiratory symptoms as "just from vaping": EVALI can be severe and requires corticosteroids 1
2. Assuming nicotine-free vapes are safe: Severe lung injury occurs with these products 1
3. Overlooking cardiac complications: TOF patients have ongoing arrhythmia and sudden death risk 6
4. Using nicotine replacement in bronchospastic disease: Contraindicated 3
5. Failing to screen for 22q11 deletion: This is a Class I recommendation for all TOF patients 5

The combination of repaired TOF, dual substance vaping, and diffuse abnormal lung sounds represents a high-risk scenario requiring immediate, coordinated multidisciplinary intervention.